The unexpected discovery may provide scientists with new insights into how cancer develops — and how to combat it.

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.

Researchers from the University of Colorado Cancer Center have solved a cellular mystery that may lead to better therapies ...

Nearly 50% of MS patients report pronounced fatigue, which has a significantly negative impact on their well-being, a Finnish ...